Visugromab Plus Nivolumab Shows Promise in Anti-PD-1 Refractory Solid Tumors by Targeting GDF-15 Pathway
Key Insights
Visugromab (CTL-002), a GDF-15 (search) neutralizing antibody, combined with nivolumab demonstrated initial efficacy in the phase 2A GDFATHER-TRIAL for patients with advanced solid tumors (search) that had relapsed or were refractory to prior anti-PD-1 (search)/PD-L1 (search) therapy.
GDF-15 (search) plays a critical role in tumoral immunosuppression by blocking immune cell entry into the tumor microenvironment and interfering with immune synapse formation, which many tumors exploit to resist immunotherapy.
The combination therapy represents a novel approach to overcome immunotherapy resistance by neutralizing GDF-15 (search)'s immunosuppressive effects and potentially restoring T-cell function in the tumor microenvironment.
The phase 2A GDFATHER-TRIAL has reported initial promising results for visugromab (CTL-002), a GDF-15 (search) neutralizing antibody, in combination with nivolumab for patients with advanced or metastatic solid tumors (search) that have relapsed or become refractory to prior anti-PD-1 (search)/PD-L1 (search) therapy. The study represents a novel approach to overcoming immunotherapy resistance by targeting the Growth and Differentiation Factor 15 (search) (GDF-15) pathway.
Targeting GDF-15 to Overcome Immunotherapy Resistance
Increasing evidence has emerged that GDF-15 (search) plays a critical role in tumoral immunosuppression. The protein not only blocks immune cell entry into the tumor microenvironment but also has a major impact on the formation of the immune synapse. Many tumors overexpress GDF-15 and have hijacked this mechanism to block immunotherapy success.
GDF-15 (search) is a TGF-β superfamily member that is physiologically expressed mainly in placenta and linked to feto-maternal tolerance. Under pathophysiologic conditions, prevention of excessive immune cell infiltration during tissue damage and cachexia induction have been ascribed to GDF-15. A recent study elucidated a mechanism by which GDF-15 inhibits LFA-1 (search) activation on CD8+ T cells, thus interfering with effector T cell recruitment to tissues.
Clinical Significance and Rationale
Several cancer (search) entities secrete high levels of GDF-15 (search), correlating with poor prognosis and reduced overall survival. To block this effect, the GDF-15 neutralizing antibody CTL-002 was generated. In preclinical models, CTL-002 demonstrated potent effector T cell shifting into tumor tissue by neutralizing GDF-15.
The GDFATHER-TRIAL builds upon earlier phase I first-in-human clinical trial results of CTL-002 in subjects with advanced-stage solid tumors (search). The progression to phase 2A represents a significant advancement in evaluating this novel therapeutic approach for patients who have exhausted standard immunotherapy options.
Addressing Unmet Medical Need
The combination of visugromab with nivolumab addresses a critical gap in cancer (search) treatment for patients whose tumors have become resistant to checkpoint inhibitor therapy. The mechanism of action differs from traditional immunotherapy approaches by specifically targeting the GDF-15 (search) pathway that tumors use to evade immune surveillance.
This therapeutic strategy offers potential for patients with anti-PD-1 (search)/PD-L1 (search) relapsed or refractory solid tumors (search), a population with limited treatment options and poor prognosis. By neutralizing GDF-15 (search)'s immunosuppressive effects, the combination therapy aims to restore the tumor microenvironment's susceptibility to immune-mediated destruction.
The GDFATHER-TRIAL's initial results provide important proof-of-concept data for this novel mechanism of overcoming immunotherapy resistance, potentially opening new avenues for treating patients with checkpoint inhibitor-refractory cancers.